Candesartan Cilexetil: A Review of its Use In the Management of Chronic Heart Failure

In this: publication
By this: publisher
In this Subject: Pharmacology ,&nbsp; <a title="Therapeutics & Alternative Medicine" href="/content/subcat?j_subject=216&j_availability=">Therapeutics & Alternative Medicine
By this author: Caroline Fenton ;&nbsp; Lesley J. Scott

Authors: Caroline Fenton; Lesley J. Scott

Source: Drugs, Volume 65, Number 4, 2005 , pp. 537-558(22)

Buy & download fulltext article:

Price: $68.55 plus tax (Refund Policy)

Abstract:

Candesartan cilexetil is the orally administered pro-drug of candesartan, a highly selective antagonist of the angiotensin II subtype 1 receptor that mediates the pressor activities of angiotensin II. Candesartan cilexetil is widely used for the treatment of hypertension and has recently been approved in Europe for the treatment of chronic heart failure (CHF) in patients with impaired left ventricular (LV) systolic function.

Results of the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) programme suggest that oral candesartan cilexetil reduces morbidity and mortality in patients with CHF and LV ejection fraction (LVEF)

40%. There are cardiovascular benefits when candesartan cilexetil is administered as an alternative to an ACE inhibitor, or as an add-on to current treatment regimens that include an ACE inhibitor, in symptomatic CHF. While tolerability is generally good, renal monitoring is required. The recent approval of candesartan cilexetil as both add-on and alternative therapy to ACE inhibitors in patients with CHF and impaired LV systolic function recognises the cardiovascular benefits of candesartan cilexetil in both types of treatment regimens.